clinical_trials
Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Confidence95·multiple reportsImportance97NP-EVT-20261021-E6FD99F
Nature Medicine, Published online: 21 October 2026; doi:10.1038/s41591-026-04747-2 Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Read the original at the primary source
Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Christos C. Zouboulis · 10/21/2026, 12:00:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —